Sentiment Trading

Summit Therapeutics Inc. has experienced a remarkable surge in market value, driven by positive Phase III trial results for its lung cancer treatment, Ivonescimab, and international recognition and approval for its use in China.

Summit Therapeutics Inc. saw a 14.7% surge in its stock price after announcing positive results from a Phase III clinical trial for its lung cancer treatment, Ivonescimab.